North American Scientific Inc. (NASI) Signs Definitive Agreement to Divest Prostate Brachytherapy Product Line
2/12/2009 10:10:22 AM
CHATSWORTH, Calif.--(BUSINESS WIRE)--North American Scientific, Inc. (Nasdaq: NASM) announced today that it has entered into a definitive agreement to sell its prostate brachytherapy product line to Best Theratronics, Ltd., part of the TeamBest Family of Companies. These products currently include Prospera® brachytherapy seeds, SurTRAK™ needles and strands and various accessories used primarily in the treatment of prostate cancer. NASM will receive $5 million for the product line, with $2 million being paid at the closing of the transaction and the remaining $3 million being paid in installments over the 12 month period following the closing.
comments powered by